Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 1;12(12):1171.
doi: 10.3390/pharmaceutics12121171.

Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations

Natalia L Klyachko  1   2 , Camryn J Arzt  2 , Samuel M Li  2 , Olesia A Gololobova  1   2 , Elena V Batrakova  1   2
Affiliations
Review

Extracellular Vesicle-Based Therapeutics: Preclinical and Clinical Investigations

Natalia L Klyachko et al. Pharmaceutics. .

Abstract

Drug nanoformulations hold remarkable promise for the efficient delivery of therapeutics to a disease site. Unfortunately, artificial nanocarriers, mostly liposomes and polymeric nanoparticles, show limited applications due to the unfavorable pharmacokinetics and rapid clearance from the blood circulation by the reticuloendothelial system (RES). Besides, many of them have high cytotoxicity, low biodegradability, and the inability to cross biological barriers, including the blood brain barrier. Extracellular vesicles (EVs) are novel candidates for drug delivery systems with high bioavailability, exceptional biocompatibility, and low immunogenicity. They provide a means for intercellular communication and the transmission of bioactive compounds to targeted tissues, cells, and organs. These features have made them increasingly attractive as a therapeutic platform in recent years. However, there are many obstacles to designing EV-based therapeutics. In this review, we will outline the main hurdles and limitations for therapeutic and clinical applications of drug loaded EV formulations and describe various attempts to solve these problems.

Keywords: clinical applications; drug delivery; extracellular vesicles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Chong S.Y., Lee C.K., Huang C., Ou Y.H., Charles C.J., Richards A.M., Neupane Y.R., Pavon M.V., Zharkova O., Pastorin G., et al. Extracellular Vesicles in Cardiovascular Diseases: Alternative Biomarker Sources, Therapeutic Agents, and Drug Delivery Carriers. Int. J. Mol. Sci. 2019;20:3272. doi: 10.3390/ijms20133272. - DOI - PMC - PubMed
    1. Boulanger C.M., Loyer X., Rautou P.E., Amabile N. Extracellular vesicles in coronary artery disease. Nat. Rev. Cardiol. 2017;14:259–272. doi: 10.1038/nrcardio.2017.7. - DOI - PubMed
    1. Zamani P., Fereydouni N., Butler A.E., Navashenaq J.G., Sahebkar A. The therapeutic and diagnostic role of exosomes in cardiovascular diseases. Trends Cardiovasc. Med. 2019;29:313–323. doi: 10.1016/j.tcm.2018.10.010. - DOI - PubMed
    1. Jia G., Sowers J.R. Targeting endothelial exosomes for the prevention of cardiovascular disease. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165833. doi: 10.1016/j.bbadis.2020.165833. - DOI - PubMed
    1. Tikhomirov R., Donnell B.R., Catapano F., Faggian G., Gorelik J., Martelli F., Emanueli C. Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis. Cells. 2020;9:592. doi: 10.3390/cells9030592. - DOI - PMC - PubMed

LinkOut - more resources